The 2027 Dermatology Prior Authorization Shift: What Changes, What Doesn't, and What to Fix Before January

Some specialty medications, biologics, phototherapy and specific dermatology procedures require timely approvals. When the vouching process is postponed, there is not fully completed or fails to be connected to the claim, then treatment plans and cash flow become a concern. Instead of just an approval, the difficulty with dermatology prior authorization is actually the process that allows you to get the approval in the first place. Teams need to keep track of the requirements of the payer, have supporting documentation, have units and dates authorized, and verify that the claim is in accord with payer approval.

While the 2027 changes draw attention to how your practice processes dermatology prior authorization, it doesn’t provide one single process for all payers and services. Some interoperability and prior authorization mandates have been finalized and other drug-related provisions are still proposed. Practice leaders need to be ready for requirements that are relevant for their payer mix and enhance operational controls that could secure reimbursement.

What Changes Under the 2027 CMS Rule?

The Interoperability and Prior Authorization Final Rule, CMS-0057-F was finalized in January 2024. It sets standards for certain payers to enhance electronic data interchange and increases the clarity of certain elements of the prior authorization process. A number of the requirements for this API typically go into effect in 2027, with either applicability and implementation dates based on payer type.

For practices, the practical value of dermatology prior authorization changes is better access to information. About covered items and services, documentation requirements, and authorization decisions where a payer and transaction fall within the rule. The Prior Authorization API is designed to facilitate electronization of prior authorizations requests and responses. A written response will let someone know whether a request is approved, refused with a reason or with a request for further information.

That isn’t to say all dermatology prior authorizations will be automated or available at the instant request. This rule is applicable to specific categories of payers. Dermatology prior authorization teams should check if a plan is covered and the specific type of plan, such as Medicare Advantage plans, Medicaid and CHIP fee-for-service, Medicaid managed care, or a CMPE or public plan that participates in a federally-facilitated exchange. The specifics vary amongst provisions.

For all medical items and services (excluding drugs), impacted payers also were subject to decision-timeframe requirements from CMS. If the payer is also the party responsible for paying, the deadline is 72 hours for expedited requests and 7 calendar days for standard requests. The timeframe provisions are not applicable to certain categories of payers, such as qualified health plan issuers on federally-facilitated exchanges. These time frames are not intended for application to every plan; practices should confirm which time frames apply to each plan.

The rule also mandates that the payers who are affected must give a specific reason for denying payment, and some provisions for operations are expected to start broadly in 2026. This detail will assist billing staff responsible for dermatology prior authorization in determining if a denial is due to an incomplete documentation issue, coverage criteria, or another reason. It doesn’t eliminate the need to return to the explainer to learn that process and abide by its appeal process.

What Does Not Change?

It is important to note that a CMS rule cannot supersede each individual payer’s medical policy and that benefit design and documentation criteria should also be reviewed by the dermatology prior authorization staff. Coverage requirements are not updated daily for procedures like biologics, specialty drugs, phototherapy or selected procedures, which dermatology practices must review before requesting them. While the adoption of an electronic tool can increase information exchange, it is not in isolation medically necessary.

Approval does not mean approval for payment of claims. The service in question must still adhere to the coverage rules and the claim submitted must accurately reflect the services rendered, service provider, date, units and other services information required. If the medication, dose, treatment location (or service delivery location) or treatment schedule approved is modified, the staff should check to see if the authorization must be updated before billing it.

When the dermatology prior authorization is given for a specific number of units or a specific period of time, this difference will make a difference. For dermatology prior authorization, the staff should document the dates the treatments were approved, the type or name of the treatment, the necessary treatment codes, quantity, any limitation, and if it’s a dermatology session. They should also be aware of who is responsible for ensuring that those aspects are reviewed when there is a change in the clinical plan.

Special care must be taken for the drug needs. As a proposed rule, CMS-0062-P introduces a long list of new interoperability and prior authorization mandates related to drugs. The offer is not a definite obligation. Previously established dermatology prior authorization practices should watch CMS for changes rather than accepting the proposed drug provisions or proposed dates as a matter of course.

Which Dermatology Services Need Authorization Review?

Required authorizations depend on the diagnosis and treatment setting, by reference to the product, plan and payer. The dermatology prior authorization process should be structured of practices around the services they deliver and the plans their patients utilize. A general checklist may not address all of the differences between a medication benefit and a medical benefit.

Biologics and specialty medications

For some conditions, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, clinical notes, history of all previous treatments, and details of the diagnosis and whether they meet the criteria for plan are required. There are some products that go through the Pharmacy benefit and some products may be covered under the medical benefit. The correct route affects which forms, portals, and billing rules apply to dermatology prior authorization.

All staff should ensure that they verify the product/s, benefit pathway, prescribing clinician/s, diagnosis, dose and support records for every request. They should consider the tasks associated with the step-therapy history and the need for other clinical information or previous medications, which the payer may request. Even if the treatment is covered, missing information can contribute to a delay in decision making.

Phototherapy and recurring treatment

When a series of services is approved, such as phototherapy, it may result in tracking issues if there is a limit on the number of visits, units, or a date range. A practice can be given an initial approval and not keep track of the extent to which the authorization is used. This difference may be whether services continue or claims are submitted for more than the required period of time.

Pre-calculate dermatology prior authorization reminders and set them before the end of the prior authorization period and assign responsibility for reviewing the remainder of visits or units. Be sure to assume no renewal! When necessary, the clinical team shall submit up to date records and give the authorization team a chance to verify this new approval before the next service that relies upon this approval.

Procedures and site-of-service requirements

There may be settings, medical policies, diagnosis or authorization requirements for some dermatologic procedures. Relevant staff who are responsible for dermatology prior authorization must ensure that the authorization relates to the intended treatment/procedure and site. Changes to the procedure, site, or treatment plan will not support the service as approved if the provider changes the procedure, site, or treatment plan.

Five Workflow Failures That Put Revenue at Risk

1. Authorization information is scattered

In the absence of these dates or service limits, staff can miss when approvals arrive in portal messages, scanned forms, in e-mail or separately on spreadsheets. Inaccurate records can also complicate matters for billing teams since they cannot be sure that a claim is supported prior to submission. Keep one by each dermatology prior authorization number. Consider the names of the payer, member and plan information, service or medical/medication, diagnosis, relevant codes, submission date, decision, reference number, effective dates, approved units, and the renewal date. Retain the approval notice and clinical documentation together or in an authorized system of the practice.

2. The approved service does not match the claim

The eventual claim covers a later detail, a claim for a specific product, code, dose, provider, or location can be approved. A clinical change might be in an appropriate direction, but the mismatch may lead to a denial or delay. Any final dermatology prior authorization process point should be a match of the approval with the service and billing. Utilize a pre-service review of costly medicines and frequent treatments. Verify the application of the approval and for the service provided. Once the material changes, establish whether the payor should amend or submit a new request prior to submitting the claim.

3. Renewals start too late

Refreshing care or revenue that is only active after an approval has ended can place care and revenue at risk. The practice may require the clinical notes, treatment response or evidence medical necessity are still ongoing to be updated. Those records take time to collect and then there are the periods of time required for the payer’s review of the records for the next treatment.

Build dermatology prior authorization renewal work queues by expiration date and/or the priorities of the payers. Schedule reminders to be received sufficiently prior to the gathering of records, the request, the answering of follow-up questions and obtaining a decision. Monitor cases for updates every day and don’t let “pending” cases get lost in the “to do” list of general tasks.

4. Supporting documentation is incomplete

Requests may fall through when the records sent do not provide information that helps clarify the reasons for the requested service, or the diagnosis or treatment. The clinical notes may be part of the record document but still do not capture those specific criteria of the payer. Adding a large chart to the submission is not a complete submission and should not be assumed as such.

Develop checklists for common services that are “payer-aware” dermatology prior authorizations. Ensure that the request specifies the diagnosis, applicable history, past treatment (if applicable), clinical justification and details about the services requested. If the payer requests more information then note the date of the request and the response owner, and provide a full response along the designated reply path.

5. Denials have no clear next step

A denial or request for additional information should trigger a defined workflow, not sit in an inbox. Teams managing dermatology prior authorization denials need to identify the reason, determine whether the issue is correctable, and assign the appropriate response. Without ownership and deadlines, a recoverable claim can age into avoidable accounts receivable. For each dermatology prior authorization denial, record the reason, appeal or correction deadline, missing evidence, responsible staff member, and next action. Distinguish and report authorization denials, coding issues and eligibility issues. Review monthly about the frequency and solve the problem at the cause of the problem rather than correct the same problems over and over.

How to Prepare Before January 2027

To begin, run a dermatology prior authorization audit on the payer mix. Understand the necessity of and identify provisions in plans that have to comply with CMS-0057-F. Be careful not to take it for granted that everything functions the same way in commercial plans or in all authorizations. Ensure needs are met as outlined in payer guidance and stay abreast of CMS changes, including those concerning drugs.

Then, draw a line through the existing process from eligibility process to request submission, to capturing a decision, to providing services, to claim submission, and to handling claims denials. Document ownership of each step and storage of status information. The objective is to uncover “hands down” delays, approvals that are allowed to lapse and billing teams missing the proof to cleanly submit a claim.

After that, simply create a standard set of data to collect for each dermatology prior authorization. For a minimum, document the reason for the decision, the approval reference, the approved units or quantity, the effective dates, the renew date, the status, the diagnosis and all codes, its relevance, the requested services and the date it was submitted. Provide this information to the clinical, authorization and bill teams based on roles and user access.

Wait to review technology until after the problem of the workflow is documented. A new platform won’t solve issues of ownership or lack of clinical documentation on its own, but can help minimize duplicate entry and facilitate status tracking. Inquire from vendors how they process payer-specific requirements, how they notify the payer for the expiring approval, store the documents, and report the issues towards the unapproved requests.

Last but not least, educate employees about change and what doesn’t change. Clarify CMS requirements; also and remind complying with individual payers. Staff must be aware of what to do if a decision is too long delayed, how to respond when requested to document and what staff check when the service and claim are made.

Measure the Financial Impact of Authorization Delays

An authorization practice should capture denials, accounts receivable, and authorization performance. The objective is to identify where delays are occurring, how frequently and whether process changes have an impact on either the treatment or billing process, or whether they impact the outcomes. Monitor dermatology prior authorization activity by payer and service line to concentrate on reoccurring challenges and not individual cases.

Useful measures include:

• Time to Decision: Average calendar time from full submission to payer decision by payer and request type.
• First-submission completeness: % of requests submitted with all the necessary information on the first attempt.
• Approval expiration incidents: The number of services that have been prevented from being provided, or number of claim affected services, due to an expired approval.
• Authorization denials rate: Percentage of claims that have no authorization, invalid authorization, expired authorization or conflicting authorization with the service billed.
• Average days in A/R-authorization: Average days that impacted claims are in A/R.
• Appeal recovery rate: Percentage of authorization denials (appealed for reason) that are reversed or paid.

The risk of exposure can be estimated by taking the count of affected claims times a reasonable average amount that the claim would balance at. Next separate the delayed amounts, corrected and paid, appealed, written off and not settled. This helps protect practices from the premature end of an event which is not considered cancelled. As an illustration, when there are 20 claims for dermatology prior authorization, and each claim is likely to have an allowed amount of $600, the initial exposure is $12,000. This is the potential lost revenue at risk, not substantiated losses. Compare the estimate against the final outcome with payers prior to reporting to leadership regarding financial impact.

How Billing Care Solutions Supports Dermatology Practices

Billing Care Solutions supports practices in implementing effective authorizations, claims and reimbursement controls throughout the revenue cycle. Dermatology prior authorization may involve eligibility and benefit verification, authorization workflow coordination, claim review, claim denial follow-up, follow-up with accounts receivable and financial reporting. This is designed to align approval processes in the front end of the work with the payment workflow for posting, thus ensuring that the services are billed for the expected reimbursement.

For dermatology prior authorization workflows, keeping records, timely follow-up and a reliable process for knowing when the order has not been approved, approved but about to expire or approved but inconsistent with the intended service are essential. Billing Care Solutions can assist practices with reviewing these handoffs, establishing follow-up tasks and finding common problems for claims. The extent should measure the practice’s payer mix, systems, services, and in-house staffing.

Dermatology prior authorization  reporting should reflect on the number of prior authorization requests made more than the amount of staff time. Practice administrators must have access to the status of future requests, outstanding cases, missing information, upcoming expiration dates, authorization denials, and claim financial information. These activities can assist managers in determining where a staffing change, documents or process of work changes will be needed.

Preparation is best done prior to becoming a denied claim or a missed treatment. Check dermatology prior authorization rules, determine who owns these rules, and walk through the workflow with a real case of your highest volume services. While it’s important that the documentation is accurate, it’s vital that they be done reliably, even if in accordance with the CMS requirements.

Final Takeaway

These changes are scheduled for the future in the year 2027 and, for this reason, dermatologists and their practices must be aware of the various requirements that CMS has implemented regarding their relationship with payers, and any other proposals that are yet to be considered. They won’t eliminate payer-specific healthcare policies or ensure quicker approval for any and all requests. The preparation period is a great time to beef up a record, track renewals, validate claims, and follow-up on denials.

A uniform dermatology prior authorization process can minimize unnecessary time and effort wasted and make reimbursement issues more transparent. Review existing workflow, document performance by payer and assign definite owners and next steps to all unfulfilled requests. Billing Care Solutions offers practices a way to determine and understand the revenue cycle gaps and implement more stable processes around claims and authorization.

Frequently Asked Questions